JMP Securities analyst Constantine Davides has maintained their neutral stance on HSTM stock, giving a Hold rating yesterday.
Constantine Davides has given his Hold rating due to a combination of factors related to HealthStream’s recent financial performance and future outlook. The company’s fourth-quarter revenue exceeded expectations, but its adjusted EBITDA fell short, and gross margin slightly missed estimates. Additionally, increased expenses in product development and sales and marketing contributed to the cautious stance.
While HealthStream’s balance sheet remains strong with significant cash reserves and no debt, the company faces challenges such as customer bankruptcies and legacy solutions impacting revenue. Despite the promising growth in certain segments and ongoing M&A activities, the anticipated headwinds in the first half of 2025 and the fair valuation of the stock at its current trading multiple support the Hold rating. The longer-term potential of HealthStream’s platform strategy is acknowledged, but near-term growth expectations remain modest.
In another report released yesterday, Canaccord Genuity also maintained a Hold rating on the stock with a $29.00 price target.